Esperion Therapeutics (ESPR) investor relations material

Executive summary

• Entered into a Merger Agreement with Essence Parent Inc. and Essence MergerCo Inc., with the company to become a wholly owned subsidiary of Parent upon completion of the merger.

• The HSR Antitrust Waiting Period expired on June 15, 2026, satisfying a key regulatory condition for the merger.

• Completion of the merger remains subject to customary closing conditions, including stockholder approval at a special meeting scheduled for July 8, 2026.

• Forward-looking statements highlight risks and uncertainties related to the merger, including regulatory approvals, potential litigation, and business disruptions.

Voting matters and shareholder proposals

• Stockholders will vote on the adoption of the Merger Agreement at a special virtual meeting on July 8, 2026.

• Proxy materials, including the Proxy Statement, have been filed and distributed to securityholders for review ahead of the meeting.

Board of directors and corporate governance

• Directors and executive officers may be deemed participants in the solicitation of proxies for the merger vote.

• Information about directors’ and officers’ interests in the transaction is available in the proxy statement and related SEC filings.